In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part II.

Bioorg Med Chem Lett 2010 Aug 11;20(15):4719-23. Epub 2010 Apr 11.

Novartis Institutes for BioMedical Research, CH-4002 Basel, Switzerland.

Spirocyclopropane- and spiroazetidine-substituted tetracycles 13D-E and 16A are described as orally active MK2 inhibitors. The spiroazetidine derivatives are potent MK2 inhibitors with IC(50)<3 nM and inhibit the release of TNFalpha (IC(50)<0.3 microM) from hPBMCs and hsp27 phosphorylation in anisomycin stimulated THP-1 cells. The spirocyclopropane analogues are less potent against MK2 (IC(50)=0.05-0.23 microM), less potent in cells (IC(50)<1.1 microM), but show good oral absorption. Compound 13E (100mg/kg po; bid) showed oral activity in rAIA and mCIA, with significant reduction of swelling and histological score.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2010.04.023DOI Listing
August 2010

Publication Analysis

Top Keywords

mk2 inhibitors
12
spiroazetidine-substituted tetracycles
4
spiroazetidine derivatives
4
inhibitors spirocyclopropane-
4
tetracycles 13d-e
4
spirocyclopropane- spiroazetidine-substituted
4
inhibitors spiroazetidine
4
described orally
4
active mk2
4
16a described
4
13d-e 16a
4
orally active
4
derivatives potent
4
vitro sar
4
inhibitors ic50
4
vivo vitro
4
sar tetracyclic
4
potent mk2
4
mapkap-k2 mk2
4
tetracyclic mapkap-k2
4

Altmetric Statistics

Similar Publications